Cftr Trikafta denied as duplicate or overlapping therapy by CVS Caremark?

Trikafta covered for FDA-labeled mutations + CF center attestation. Symdeko/Orkambi non-preferred when Trikafta-eligible.

CFF 2023 Modulator Recommendations + CFTR2 database for non-F508del responsive variants. April 2023 FDA expansion to age 2-5 (VX20-445-111). Step-therapy through inferior modulator contradicts CFF first-line Trikafta recommendation.

## Why CVS Caremark Denies Trikafta as Duplicate Therapy

CVS Caremark's duplicate therapy edit flags when a member appears to have another drug in the same therapeutic class already on file — either currently dispensed or recently filled. For CFTR modulator therapies, this can occur if a patient is transitioning from a prior-generation modulator (such as a single-component or two-component regimen) to the triple-combination therapy, and the pharmacy system shows an overlapping fill. It can also be triggered by a data entry error or claims system lag. This type of denial is often resolved quickly, but must be addressed carefully to ensure the transition is properly documented.

## Your Federal Appeal Rights

Duplicate therapy denials are adverse benefit determinations subject to the same appeal rights as clinical denials. Under ACA §2719 and ERISA §503, you have the right to internal appeal and external independent review. You typically have 180 days from the denial to file internally, and four months after an internal denial to escalate to external review. Expedited review is available when a delay would jeopardize health.

## The Concrete Appeal Process

1. Contact CVS Caremark directly to identify which drug the system flagged as duplicative. Request the specific NDC or drug name the system identified. 2. Determine whether this is a system error or a genuine transition scenario — if the patient is switching from a prior modulator to this triple combination, that is a substitution, not a duplication. 3. Have the prescriber's office submit a prior authorization or exception request clarifying that the prior-generation therapy is being discontinued and the triple combination is the new, sole therapy. 4. If not resolved administratively, file a formal written internal appeal. 5. If denied internally, request independent external review.

## Documentation to Gather

• Prescriber letter confirming therapeutic substitution — explicitly stating the prior modulator is being discontinued and the triple combination is the replacement, not an addition
• Confirmed CFTR genotype report confirming the patient is eligible for the triple combination under its FDA-approved indication
• Current medication list signed by the prescriber, showing the prior modulator is no longer prescribed
• Pharmacy records showing the prior therapy fill dates and that the overlap is transitional rather than concurrent
• FDA prescribing labels for both drugs, demonstrating they are distinct products with distinct clinical profiles

## Criteria-Mapping Structure

Request CVS Caremark's duplicate therapy edit criteria. Then map:

| Edit Parameter | Patient Documentation | |---|---| | Drugs flagged as duplicative | Identity of both drugs + NDCs | | Clinical distinction between therapies | FDA label comparison — different component combinations | | Transition vs. concurrent use | Prescriber letter + pharmacy records showing substitution | | Discontinuation of prior therapy | Updated prescription + medication list |

The key argument is that a transition from a less comprehensive modulator regimen to a more comprehensive one is a clinically directed substitution, not duplication. Prescriber documentation of discontinuation and the genotype-specific rationale for upgrading therapy typically resolves this denial at the administrative or first-appeal level.